EDCTP Annual Report 2019 – steering a portfolio for impact

PredictTB's funder, the European & Developing Countries Clinical Trials Partnership (EDCTP), published its Annual Report 2019 on August 14, 2020. The report shows the steady growth, scope, and cohesion of the project portfolio, and highlights the progress made towards the objectives of the programme.

The EDCTP is a public-public partnership between 14 European and 16 African countries, supported by the European Union. Its mission is to accelerate the development of new or improved medicinal products for the identification, treatment, and prevention of infectious diseases, including emerging and re-emerging diseases, through pre- and post-registration clinical studies, with emphasis on phase II and III clinical trials.

EDCTP-funded grants support activities at more than 200 institutions in 37 countries in sub-Saharan Africa and at 150 institutions in 16 European countries. The earlier account for 57.6% of total EDCTP funding, a proof of the programme’s objective to ‘increase cooperation with sub-Saharan Africa through capacity building for conducting clinical trials according to ethical principles and regulatory standards’.

The programme’s other main objectives are to:

Ten new calls for proposal were launched in 2019, bringing the total number of the second EDCTP programme (EDCTP2) calls to 53.

Source: EDCTP Annual Report 2019 / Concept and design: Daniela Pereira

271 grants supported by the EDCTP2 2014-2019

By the end of 2019, the number of grants supported by EDCTP2 since 2014 reached 271. A complete list of the partnership’s projects can be found here.

The total funding provided by the EDCTP between 2014 and 2019 amounts to €608.41 M. Most funding was awarded to the EDCTP’s 84 collaborative clinical trials and clinical studies, which received in total €526.04 M. The partnership awarded €51.27 M to 57 clinical research capacity strengthening projects and €31.10 M to 130 fellowships that focus on the career development of individual researchers.

Source: EDCTP Annual Report 2019 / Concept and design: Daniela Pereira

Portfolio focused on the EDCTP’s priority areas

The EDCTP portfolio is well-balanced, with 63.1% of projects being focused on the three major poverty-related infectious diseases (HIV and HIV-associated infections, tuberculosis, and malaria), 15.5% on neglected infectious diseases, 10.7% on emerging and re-emerging infections, and 10.7% on diarrhoeal diseases and lower respiratory tract infections.

Professor Yazdan Yazdanpanah, Chair of the EDCTP General Assembly, writes in his foreword to the EDCTP Annual Report 2019 that “By focusing on specific priority areas, we can ensure that we achieve true impact, and can be more strategic in the kind of support we provide. By recognising our niche, we can also better identify potential partners and ensure our activities align and complement those of others.”

30% of EDCTP’s collaborative clinical research grants focus on tuberculosis

Of the 84 collaborative clinical trials and clinical studies included in the EDCTP’s portfolio, almost 30% (24 projects) focus on tuberculosis. The number of tuberculosis-oriented projects is almost as high as that of projects that focus on malaria (12 grants) and HIV and HIV-associated infections (16) combined.

Divided by disease, tuberculosis-focused projects received 27.9% (€146.73 M) of the total funding (€526.04 M) awarded by the EDCTP to its collaborative clinical research projects between 2014 and 2019.

The full online publication of the EDCTP Annual Report 2019 can be found here. And a summary version can be downloaded (as a PDF) here.

Source: EDCTP Annual Report 2019 / Concept and design: Daniela Pereira